Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ping Chi

Showing results (211-220 of 264) with videos related to

Pageof 27
Sort By:
JCO Precision Oncology|December 7, 2020
Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway GenesEvan Rosenbaum, Philip Jonsson, Kenneth Seier, et al.
Investigational New Drugs|August 14, 2018
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumorCiara M Kelly, Alexander N Shoushtari, Li-Xuan Qin, et al.
The Journal of Clinical Investigation|January 24, 2018
COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitorsYuanyuan Xie, Zhen Cao, Elissa Wp Wong, et al.
The Oncologist|July 27, 2021
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS StudyJohn R Zalcberg, Michael C Heinrich, Suzanne George, et al.
The Lancet. Oncology|July 8, 2024
Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort studyDimitris Bertsimas, Georgios Antonios Margonis, Suleeporn Sujichantararat, et al.
Science Advances|April 5, 2023
ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancerDan Li, Yu Zhan, Naitao Wang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|September 7, 2024
Comprehensive genomic profiling in multiple cancer types: A comparative analysis of the National Biobank Consortium of Taiwan and clinical practice cohortsLing-Jen Hung, Chen-Yang Huang, Kai-Che Tung, et al.
The Journal of Clinical Investigation|June 24, 2025
BET inhibitors reduce tumor growth in preclinical models of gastrointestinal gene signature-positive castration-resistant prostate cancerShipra Shukla, Dan Li, Woo Hyun Cho, et al.
Cancer Discovery|December 15, 2020
SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation TherapiesMahesh Saqcena, Luis Javier Leandro-Garcia, Jesper L V Maag, et al.
Biorxiv : the Preprint Server for Biology|February 27, 2026
Cell-Autonomous AR Dependence in Luminal Prostatic Epithelium Governs Survival and Lineage PlasticityDan Li, Naitao Wang, Wangxin Guo, et al.
Pageof 27

Showing results (211-220 of 264) with videos related to

Sort By:
Pageof 27
JCO Precision Oncology|December 7, 2020
Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway GenesEvan Rosenbaum, Philip Jonsson, Kenneth Seier, et al.
Investigational New Drugs|August 14, 2018
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumorCiara M Kelly, Alexander N Shoushtari, Li-Xuan Qin, et al.
The Journal of Clinical Investigation|January 24, 2018
COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitorsYuanyuan Xie, Zhen Cao, Elissa Wp Wong, et al.
The Oncologist|July 27, 2021
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS StudyJohn R Zalcberg, Michael C Heinrich, Suzanne George, et al.
The Lancet. Oncology|July 8, 2024
Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort studyDimitris Bertsimas, Georgios Antonios Margonis, Suleeporn Sujichantararat, et al.
Science Advances|April 5, 2023
ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancerDan Li, Yu Zhan, Naitao Wang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|September 7, 2024
Comprehensive genomic profiling in multiple cancer types: A comparative analysis of the National Biobank Consortium of Taiwan and clinical practice cohortsLing-Jen Hung, Chen-Yang Huang, Kai-Che Tung, et al.
The Journal of Clinical Investigation|June 24, 2025
BET inhibitors reduce tumor growth in preclinical models of gastrointestinal gene signature-positive castration-resistant prostate cancerShipra Shukla, Dan Li, Woo Hyun Cho, et al.
Cancer Discovery|December 15, 2020
SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation TherapiesMahesh Saqcena, Luis Javier Leandro-Garcia, Jesper L V Maag, et al.
Biorxiv : the Preprint Server for Biology|February 27, 2026
Cell-Autonomous AR Dependence in Luminal Prostatic Epithelium Governs Survival and Lineage PlasticityDan Li, Naitao Wang, Wangxin Guo, et al.
Pageof 27